<DOC>
	<DOCNO>NCT00488514</DOCNO>
	<brief_summary>This study design determine long-term safety TREXIMET ( sumatriptan/naproxen sodium ) adolescents acute treatment migraine .</brief_summary>
	<brief_title>Long-Term Safety Treximet ( Sumatriptan/Naproxen Sodium ) Migraine Adolescents</brief_title>
	<detailed_description>This study design determine long-term safety TREXIMET ( sumatriptan/naproxen sodium ) adolescent ( age 12 17 year ) acute treatment migraine .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Subject 12 17 year old Screening visit . If subject female , must negative urine pregnancy test screening , plan become pregnant course study agree use acceptable method birth control ( i.e. , method failure rate &lt; 1 % abstinence ) is/becomes sexually active . Subject migraine without aura ( 2004 ICHDII criterion ) . Subject history suggestive typical migraine attack duration 2 hour ( untreated , unsuccessfully treat ) . Subject least 2 , 8 , migraine attack per month 2 month prior Screening visit . Subject least 6month history moderate severe migraine attack , sufficient establish definitive diagnosis migraine . Subject able distinguish migraine headache ( e.g. , tensiontype headache ) . Subject subject 's parent legal guardian willing able provide inform consent prior entry treatment phase study . Subject subject 's parent legal guardian able read write English Spanish . Subject able understand complete electronic device report treatment information . Subject &lt; 75 pound ( 33.3kg ) . Subject â‰¥15 headache day per month total , retinal ( ICHDII 1.4 ) , basilar ( ICHDII 1.26 ) hemiplegic migraine ( ICHDII 1.25 ) , secondary headache . Subject , investigator 's opinion , likely unrecognized cardiovascular cerebrovascular disease ( See Appendix 1 , section 11.1 ) . Subject uncontrolled hypertension ( See Appendix 2 , section 11.2 ) take angiotensinconverting enzyme ( ACE ) inhibitor angiotensin receptor blocker . Subject history congenital heart disease , cardiac arrhythmia require medication , history clinically significant electrocardiogram abnormality , investigator 's opinion , contraindicate participation study . Subject evidence history ischemic vascular disease include : ischemic heart disease , ischemic abdominal syndrome , peripheral vascular disease Raynaud 's Syndrome , signs/symptoms consistent . Subject evidence history central nervous system pathology include stroke and/or transient ischemic attack ( TIAs ) , epilepsy structural brain lesion lower convulsive threshold ; treat antiepileptic drug seizure control within 5 year prior screen . Subject history impair hepatic renal function , investigator 's opinion , contraindicate participation study . Subject hypersensitivity , allergy , intolerance , contraindication use triptan , NSAID aspirin ( include sumatriptan naproxen preparation ) nasal polyps asthma . Subject currently take , take previous three month , migraine prophylactic medication contain methysergide dihydroergotamine ; take medication stabilize ( i.e. , change dose within past 2 month ) either chronic intermittent migraine prophylaxis comorbid condition stabilize . Subject recent history regular use opioids barbiturates treatment his/her migraine headache and/or nonmigraine pain . Regular use define average 4 day per month last 6 month . Subject take , plan take , monoamine oxidase inhibitor ( MAOI ) , include herbal preparation contain St. John 's Wort ( Hypericum perforatum ) , anytime within 2 week prior screen 2 week post final study treatment . Subject history bleed disorder currently take anticoagulant antiplatelet agent . Subject evidence history gastrointestinal surgery GI ulceration perforation past six month , gastrointestinal bleeding past year ; evidence history inflammatory bowel disease . Subject test positive illicit substance toxicology screen , evidence alcohol substance abuse within last year , concurrent medical psychiatric condition , investigator 's judgment , likely interfere study conduct , subject cooperation , evaluation interpretation study result , otherwise contraindicate participation clinical trial . Subject participate investigational drug trial within previous 4 week plan participate another study time study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Long-term Safety</keyword>
	<keyword>Migraine</keyword>
	<keyword>Adolescent Migraine Headache</keyword>
	<keyword>sumatriptan succinate</keyword>
	<keyword>naproxen sodium</keyword>
</DOC>